Faron Pharmaceuticals Oy's (LON:FARN) chief executive Dr Markku Jalkanen tells Proactive London's Andrew Scott its drug Traumakine has been admitted to a large-scale global programme that will assess its potential in treating severe pneumonia.
The study also includes patients suffering from the latest virus outbreak.
The interferon beta-1 formulation will be delivered intravenously, which he says offers the best “delivery route” for critically ill patients.
